These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20488540)

  • 1. Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis.
    Minarik J; Scudla V; Ordeltova M; Pika T; Bacovsky J; Steinbach M; Kumar V; Van Ness B
    Leuk Res; 2011 Jan; 35(1):44-8. PubMed ID: 20488540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
    Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of plasmatic cell proliferation and apoptosis indexes in the course of multiple myeloma].
    Minarík J; Scudla V; Ordeltová M; Bacovský J; Zemanová M; Pika T
    Vnitr Lek; 2008 Jan; 54(1):31-5. PubMed ID: 18390115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma].
    Scudla V; Pika T; Budíková M; Ordeltová M; Minarík J; Zemanová M; Bacovský J; Srovnalík K;
    Cas Lek Cesk; 2006; 145(12):929-35. PubMed ID: 17323615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of plasma cell propidium-iodide and annexin-V indices: their relation to prognosis in multiple myeloma.
    Minarík J; Scudla V; Ordeltová M; Bacovský J; Zemanová M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):271-4. PubMed ID: 16601769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
    Kumar S; Rajkumar SV; Greipp PR; Witzig TE
    Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
    Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A
    Haematologica; 1999 Oct; 84(10):905-10. PubMed ID: 10509038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of plasma cell proliferative and apoptotic indices in the course of multiple myeloma.
    Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
    Leuk Lymphoma; 2009 Dec; 50(12):1983-91. PubMed ID: 19860618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases].
    Ben Abid H; Meddeb B; Ben Abdallah M; Bel Hadj Ali Z; Hafsia R; Ben Lakhal R; Gouider E; Aissaoui L; Landoulsi I; ben Abdeladhim A; Hafsia A
    Tunis Med; 2000 Dec; 78(12):705-12. PubMed ID: 11155374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.
    Moreau P; Robillard N; Avet-Loiseau H; Pineau D; Morineau N; Milpied N; Harousseau JL; Bataille R
    Haematologica; 2004 May; 89(5):547-51. PubMed ID: 15136217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
    Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
    Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of multiple myeloma: a report of 182 cases].
    Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cell balance between apoptosis and proliferation in colon cancer and its correlation with prognosis].
    Chen JM; Li WH; Wang JD; Feng YD; Wu JH; Gong JP
    Ai Zheng; 2005 May; 24(5):554-8. PubMed ID: 15890096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.